Menlo Therapeutics Inc. (Nasdaq: MNLO) (“Menlo” or the “Company”) announced today the completion of its merger with Foamix Pharmaceuticals Ltd. (Nasdaq: FOMX) (“Foamix”) following the satisfaction of all closing conditions required by the merger agreement. Upon completion of the merger, pursuant to the terms of the merger agreement, Foamix became a wholly owned subsidiary of Menlo. Menlo Therapeutics Inc. is a different type of biopharmaceutical company working to solve some of today’s most difficult therapeutic challenges in dermatology and beyond.
Read the full article: Menlo Therapeutics and Foamix Pharmaceuticals Complete Merger //
Source: https://www.prnewswire.com/news-releases/menlo-therapeutics-and-foamix-pharmaceuticals-complete-merger-creating-a-combined-company-focused-on-the-development-and-commercialization-of-therapeutics-for-dermatologic-indications-301019699.html